JP2023549925A5 - - Google Patents

Info

Publication number
JP2023549925A5
JP2023549925A5 JP2023530586A JP2023530586A JP2023549925A5 JP 2023549925 A5 JP2023549925 A5 JP 2023549925A5 JP 2023530586 A JP2023530586 A JP 2023530586A JP 2023530586 A JP2023530586 A JP 2023530586A JP 2023549925 A5 JP2023549925 A5 JP 2023549925A5
Authority
JP
Japan
Prior art keywords
seq
antibody
heavy chain
light chain
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549925A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/060871 external-priority patent/WO2022112942A2/en
Publication of JP2023549925A publication Critical patent/JP2023549925A/ja
Publication of JP2023549925A5 publication Critical patent/JP2023549925A5/ja
Pending legal-status Critical Current

Links

JP2023530586A 2020-11-24 2021-11-23 抗cd48抗体、抗体薬物コンジュゲート及びその使用 Pending JP2023549925A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117817P 2020-11-24 2020-11-24
US63/117,817 2020-11-24
PCT/IB2021/060871 WO2022112942A2 (en) 2020-11-24 2021-11-23 Anti-cd48 antibodies, antibody drug conjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549925A JP2023549925A (ja) 2023-11-29
JP2023549925A5 true JP2023549925A5 (cg-RX-API-DMAC7.html) 2024-12-03

Family

ID=78819811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530586A Pending JP2023549925A (ja) 2020-11-24 2021-11-23 抗cd48抗体、抗体薬物コンジュゲート及びその使用

Country Status (20)

Country Link
US (2) US11999786B2 (cg-RX-API-DMAC7.html)
EP (1) EP4251648A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023549925A (cg-RX-API-DMAC7.html)
KR (1) KR20230112128A (cg-RX-API-DMAC7.html)
CN (1) CN116615252A (cg-RX-API-DMAC7.html)
AR (1) AR124139A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021388021A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200858A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001483A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008051A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230283A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000102A (cg-RX-API-DMAC7.html)
EC (1) ECSP23045888A (cg-RX-API-DMAC7.html)
IL (1) IL303059A (cg-RX-API-DMAC7.html)
JO (1) JOP20230112A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006010A (cg-RX-API-DMAC7.html)
PE (1) PE20240225A1 (cg-RX-API-DMAC7.html)
TW (1) TWI906417B (cg-RX-API-DMAC7.html)
UY (1) UY39533A (cg-RX-API-DMAC7.html)
WO (1) WO2022112942A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
CN120965882B (zh) * 2025-08-21 2026-04-21 合肥综合性国家科学中心大健康研究院 抗猪b细胞表面cd20的抗体或其抗原结合片段及其组合物和应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 eph 수용체 항체
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
US9097717B2 (en) 2009-04-10 2015-08-04 Osaka University Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
US8795135B2 (en) 2009-09-01 2014-08-05 Ford Global Technologies, Llc Method for controlling an engine during a restart
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
JP2015510200A (ja) 2012-02-20 2015-04-02 ノウリ コリア インコーポレイテッドKnowre Korea Inc. 知識ユニットに基づいて教育サービスを提供するための方法、システム、およびコンピュータ読み取り可能な記録媒体
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
NZ710385A (en) 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
BR112016020065A2 (pt) 2014-03-12 2018-02-20 Novartis Ag sítios específicos para modificar anticorpos para fazer imunoconjugados
MA39740A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
KR20170128256A (ko) 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
UY38265A (es) 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CN110835316A (zh) * 2018-08-17 2020-02-25 中国人民解放军军事科学院军事医学研究院 连接子、含连接子的抗体偶联药物及连接子的用途
WO2020053742A2 (en) * 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies

Similar Documents

Publication Publication Date Title
DK1976880T3 (en) Pharmaceutical compositions with resistance to soluble cea
JP6273214B2 (ja) がんを処置するためのインテグリンαvβ6に対する抗体およびその使用
JP2022511351A5 (cg-RX-API-DMAC7.html)
JP2022093564A5 (cg-RX-API-DMAC7.html)
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2021527431A5 (cg-RX-API-DMAC7.html)
EP3880712A1 (en) MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
JP2020528750A5 (cg-RX-API-DMAC7.html)
JP2017186337A5 (cg-RX-API-DMAC7.html)
JP2020534250A5 (cg-RX-API-DMAC7.html)
JP2017522871A5 (cg-RX-API-DMAC7.html)
US20060246077A1 (en) Use of antibodies against the MUC18 antigen
EP1467756A2 (en) Methods for using anti-muc18 antibodies
WO2003057838A2 (en) Antibodies against the muc18 antigen
JP2010535713A5 (cg-RX-API-DMAC7.html)
KR20160046914A (ko) 신규한 sez6 조절물질 및 사용방법
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2014524902A5 (cg-RX-API-DMAC7.html)
TW200918556A (en) Treatment of tumors using specific anti-L1 antibody
JP2022512401A5 (cg-RX-API-DMAC7.html)
JP2023509214A5 (cg-RX-API-DMAC7.html)
JPWO2020040245A5 (cg-RX-API-DMAC7.html)
JP2023517754A5 (cg-RX-API-DMAC7.html)
JP2023509215A5 (cg-RX-API-DMAC7.html)